Kilitch Drugs is currently trading at Rs. 99.25, up by 4.70 points or 4.97% from its previous closing of Rs. 94.55 on the BSE.
The scrip opened at Rs. 99.25 and has touched a high and low of Rs. 99.25 and Rs. 99.25 respectively. So far 5848 shares were traded on the counter.
The BSE group 'T' stock of face value Rs. 10 has touched a 52 week high of Rs. 140.65 on 30-Dec-2019 and a 52 week low of Rs. 63.00 on 13-Mar-2020.
Last one week high and low of the scrip stood at Rs. 96.25 and Rs. 91.35 respectively. The current market cap of the company is Rs. 153.78 crore.
The promoters holding in the company stood at 68.70%, while Non-Institutions held 31.30%.
Kilitch Drugs’ subsidiary Company -- Kilitch Estro Biotech PLC, Ethiopia, has received the manufacturing license to produce ‘Cephalosporin’ Dry Powder Injections / Tablets / Capsules & Dry syrup at Kilitch Estro Biotech PLC, Addis Ababa, Ethiopia with effective from December 18, 2020.
The company has setup the state of art dedicated Cephalosporin facility and production of the same will commence soon. This facility will help to address the immense prospects in Ethiopian local market and African continent. Grant of manufacturing license is a stepping stone for Kilitch foray in Africa & this expansion would ensure volume growth and better profitability in coming years ahead.
Kilitch Drugs is a pharmaceutical company, its services range from manufacturing to marketing a host of formulations in all dosage forms i.e. solid, liquid and parenteral forms.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1854.15 |
Dr. Reddys Lab | 1350.75 |
Cipla | 1497.80 |
Lupin | 2357.65 |
Zydus Lifesciences | 1001.20 |
View more.. |